Summary & Overview
CPT 0661T: Intraocular Drug‑Delivery Implant Exchange
CPT code 0661T captures a single, discrete ophthalmic procedure: removal of a previously placed anterior-segment, controlled‑release drug implant and immediate replacement with a new implant. The code matters nationally as advanced sustained‑release ocular implants become more common for chronic anterior‑segment conditions such as glaucoma, shifting care to ambulatory surgical settings and raising questions about access, coding clarity, and payer coverage policies. Key payers in the national landscape include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
This publication provides a concise overview of clinical context, coding scope, and the operational settings where the service is delivered. Readers will find benchmark and coverage considerations relevant to this procedure, a summary of common modifiers encountered in claims, and the clinical rationale for implant exchange versus other glaucoma treatments. The material is organized for clinicians, billing professionals, and policy analysts seeking a clear, national perspective on how CPT code 0661T is used and reimbursed across major payers. Data not available in the input will be noted where applicable.
Billing Code Overview
CPT code 0661T describes the removal of a previously placed intraocular drug-delivery implant from the anterior segment of the eye followed by implantation of a new controlled‑release device that delivers medication to treat conditions such as glaucoma. The service involves explantation of the existing ocular implant and immediate replacement with a new implant designed to provide sustained drug delivery to the front-most region of the eye.
-
Service type: Surgical implant exchange with intraocular drug delivery
-
Typical site of service: Ambulatory surgical center or hospital outpatient department where ophthalmic implant procedures are performed
Clinical & Coding Specifications
Clinical Context
A 68-year-old patient with medically uncontrolled primary open-angle glaucoma returns to the ophthalmology clinic for management after an earlier placement of an anterior-segment, drug-delivery ocular implant designed to release medication over time. The patient reports progressive visual field loss and fluctuating intraocular pressure despite topical therapy. Examination demonstrates a functioning but depleted implant and signs of disease progression in the treated eye. The provider schedules a same-day procedure to explant the depleted device and replace it with a new implant that delivers a controlled-release glaucoma medication into the anterior chamber.
The clinical workflow includes preoperative evaluation (history, medication reconciliation, informed consent, ocular exam, visual acuity, intraocular pressure measurement), perioperative topical and/or local anesthesia, sterile preparation, removal of the existing anterior-segment implant, insertion and securement of the new controlled-release implant, wound closure or intraocular tamponade as indicated, and immediate postoperative assessment. Post-procedure care involves topical antibiotics and anti-inflammatory agents, intraocular pressure monitoring, and scheduled follow-up visits to assess implant position, ocular inflammation, and therapeutic effect.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when work effort substantially exceeds typical for due to complexity or extensive additional procedures. |